Unknown

Dataset Information

0

Antigen-Specific Immunotherapy with Thyrotropin Receptor Peptides in Graves' Hyperthyroidism: A Phase I Study.


ABSTRACT: Background: Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. Methods: Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of ATX-GD-59 administered intradermally over an 18-week period. Adverse events, tolerability, changes in serum free thyroid hormones, and TSHR autoantibodies were measured. Results: Ten subjects received all 10 doses of ATX-GD-59, five (50%) of whom had free triiodothyronine within the reference interval by the 18-week visit. Two further subjects had improved free thyroid hormones by the end of the study (7/10 responders), whereas three subjects showed worsening thyrotoxicosis during the study. Serum TSHR autoantibody concentrations reduced during the study and correlated with changes in free thyroid hormones (r?=?0.85, p?=?0.002 for TSHR autoantibody vs. free triiodothyronine). Mild injection-site swelling and pain were the most common adverse events. Conclusions: These preliminary data suggest that ATX-GD-59 is a safe and well-tolerated treatment. The improvement in free thyroid hormones in 70% of subjects receiving the medication suggests potential efficacy as a novel treatment for Graves' hyperthyroidism.

SUBMITTER: Pearce SHS 

PROVIDER: S-EPMC6648194 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature

altmetric image

Publications


<b><i>Background:</i></b> Graves' disease is one of the most common autoimmune conditions, but treatment remains imperfect. This study explores the first-in-human use of antigen-specific immunotherapy with a combination of two thyrotropin receptor (TSHR) peptides (termed ATX-GD-59) in Graves' hyperthyroidism. <b><i>Methods:</i></b> Twelve participants (11 female) with previously untreated mild to moderate Graves' hyperthyroidism were enrolled in a Phase I open label trial to receive 10 doses of  ...[more]

Similar Datasets

| S-EPMC2646531 | biostudies-literature
| S-EPMC5759289 | biostudies-literature
| S-EPMC1180562 | biostudies-literature
| S-EPMC5527187 | biostudies-literature
| S-EPMC7567404 | biostudies-literature
| S-EPMC2613050 | biostudies-literature
| S-EPMC377458 | biostudies-literature
| S-EPMC7236601 | biostudies-literature
| S-EPMC9067381 | biostudies-literature
| S-EPMC3407388 | biostudies-literature